Every 424B that Thermo Fisher Scientific Inc. (TMO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow TMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TMO filings page.
Thermo Fisher Scientific is offering $3.8 billion of senior unsecured notes across four tranches: $1.0 billion 4.215% notes due 2031, $750 million 4.550% notes due 2033, $1.3 billion 4.902% notes due 2036 and $750 million 5.546% notes due 2046. The notes price near par, generating gross proceeds of about $3.80 billion and net proceeds of about $3.76 billion after $25.7 million of underwriting discounts and estimated expenses. Thermo Fisher plans to use the cash mainly to fund the pending Clario acquisition, a clinical trial data business valued at $8.875 billion in cash plus up to $525 million of additional consideration. The company reports preliminary 2025 results showing fourth‑quarter revenue up 7% to $12.21 billion and full‑year revenue up 4% to $44.56 billion, with diluted EPS rising to $5.21 for the quarter and $17.74 for the year. The notes include standard investment‑grade style covenants, optional redemption features, and a change‑of‑control repurchase at 101% of principal.
Thermo Fisher Scientific Inc. is launching a multi‑tranche senior notes offering of unsecured senior debt, with each series paying semiannual interest and featuring optional redemption and change‑of‑control repurchase protections. The notes rank equally with other unsecured senior debt and are structurally subordinated to subsidiary obligations.
Thermo Fisher plans to use the net proceeds primarily to fund the cash portion of its pending Clario Holdings acquisition, with any remainder available for general corporate purposes, including other acquisitions, debt repayment, capital spending or share repurchases. The company also reports preliminary 2025 results showing fourth‑quarter revenue of $12.21 billion versus $11.40 billion and diluted EPS of $5.21 versus $4.78, with full‑year revenue of $44.56 billion versus $42.88 billion and EPS of $17.74 versus $16.53.
Thermo Fisher Scientific (Finance I) B.V., fully guaranteed by Thermo Fisher Scientific Inc., is issuing €2,100,000,000 of senior euro-denominated notes, split between €1,000,000,000 floating rate notes due 2027 and €1,100,000,000 3.628% fixed rate notes due 2035. The floating notes pay 3‑month EURIBOR plus 0.280% with a zero floor and quarterly interest, while the fixed notes pay annual interest at 3.628%. Both issues are unsecured senior obligations and rank equally with other senior unsecured debt of the issuer and guarantor.
The notes are offered at 100% of principal, with underwriting discounts of 0.200% on the floating notes and 0.400% on the fixed notes, generating estimated net proceeds of about €2.09 billion. Thermo Fisher intends to use the cash for general corporate purposes, including potential acquisitions, debt repayment, capital spending, working capital or share repurchases, and may invest proceeds temporarily in short-term instruments. The company also highlights a pending $8.875 billion cash acquisition of Clario Holdings and a recent $2.48 billion U.S. dollar notes offering, underscoring ongoing balance sheet and strategic activity.
Thermo Fisher Scientific (Finance I) B.V., a Dutch finance subsidiary of Thermo Fisher Scientific Inc., plans to issue euro-denominated floating-rate and fixed-rate senior notes fully and unconditionally guaranteed by Thermo Fisher. The floating notes will pay interest at 3‑month EURIBOR plus a spread with a zero floor, while the fixed notes pay a set annual coupon; both are unsecured senior obligations with no sinking fund.
Thermo Fisher intends to use the euro notes’ net proceeds for general corporate purposes, which may include acquisitions, debt repayment or refinancing, working capital, capital expenditures and share repurchases. The company recently agreed to acquire Clario Holdings, Inc. for $8.875 billion in cash plus up to $525 million of additional and contingent consideration, and in October 2025 issued $2.5 billion of U.S. dollar senior notes for similar corporate uses.
The notes are expected to be listed on the New York Stock Exchange and cleared through Euroclear and Clearstream. Key features include optional redemption for the fixed notes, tax-related redemption rights, a change-of-control repurchase at 101% of principal plus interest, and payment of additional amounts to address specified Dutch and U.S. withholding taxes.
Thermo Fisher is offering multiple series of unsecured senior notes to be issued in global book-entry form through DTC, with interest payable semi-annually beginning in 2026. The notes will rank equally with Thermo Fisher's other unsecured senior debt and senior to any subordinated debt; they will be structurally subordinated to subsidiary indebtedness and effectively subordinated to any future secured debt. As of June 28, 2025, Thermo Fisher and its subsidiaries had approximately $35.23 billion of consolidated indebtedness, $5.00 billion of revolver availability and subsidiaries had $6.99 billion of indebtedness to which the notes would be structurally subordinated. The prospectus describes optional redemption mechanics, a 101% repurchase obligation upon a Change of Control Triggering Event, trustee (The Bank of New York Mellon Trust Company, N.A.), governing law (New York) and various tax and withholding provisions. Several specific offering terms (aggregate amounts, coupon rates, exact maturities and some dates) are redacted in the provided text.